During his more than 25 years at Gimv, Bart Diels has built a successful and broad full cycle track record, both in early and late stage investments, in business building, buy & build strategies and exit (IPO & trade sale) and this in different sectors.
Bart guided early stage companies such as BAI, Coreoptics, eXimius, Filepool and Metris from a smart idea towards a rewarding exit. Also later stage deals such as Acertys, Almaviva, FICS, LMS and OTN Systems were successfully sold. Today, Bart is a board member at Arseus Medical, Eurocept and Spineart. In addition to his deal experience, Bart was also very instrumental in building out Gimv’s Venture Capital team and practice. His broad experience will be vital in further expanding Gimv’s Health & Care platform, which he has been leading since the end of 2012.
Bart holds a Master’s degree in Financial and Quantitative Economics and an MBA, both from the University of Antwerp (Belgium).